Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747166 | 1.00 | ADAM17 (0.51) | ADAM17KDM4EHSD17B10HPGDMMP9 | |
| SCHEMBL19339797 | 0.89 | ADAM17 (0.53) | ADAM17KDM4EHSD17B10HPGDMMP9 | |
| SCHEMBL2708537 | 0.89 | ADAM17 (0.53) | ADAM17KDM4EHSD17B10HPGDMMP9 | |
| SCHEMBL3643559 | 0.89 | ADAM17 (0.50) | ADAM17KDM4EHSD17B10HPGDMMP9 | |
| SCHEMBL8486002 | 0.89 | ADAM17 (0.49) | ADAM17KDM4EKMT2AMEN1 | |
| SCHEMBL9082551 | 0.89 | ADAM17 (0.49) | ADAM17KDM4EKMT2AMEN1 | |
| SCHEMBL23677867 | 0.88 | ADAM17 (0.48) | ADAM17KDM4EHSD17B10HPGDMMP9 | |
| SCHEMBL18395400 | 0.88 | ADAM17 (0.48) | ADAM17KDM4EHSD17B10HPGDMMP9 | |
| SCHEMBL5827687 | 0.86 | ITGA4 (0.49) | ADAM17KDM4EMMP9MMP8KMT2A | |
| SCHEMBL5827689 | 0.86 | ITGA4 (0.49) | ADAM17KDM4EMMP9MMP8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3954369-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Lumos Pharma, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3613420-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Newlink Genetics Corporation (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248739-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | ADAM17 2252/4885KDM4E 479/4885HSD17B10 2226/4885 |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | IDO1, IDO2, INMT | ADAM17 2252/4885KDM4E 479/4885HSD17B10 2226/4885 |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | ADAM17 2252/4885KDM4E 479/4885HSD17B10 2226/4885 |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | ADAM17 2252/4885KDM4E 479/4885HSD17B10 2226/4885 |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | ADAM17 2252/4885KDM4E 479/4885HSD17B10 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.